{
    "clinical_study": {
        "@rank": "14848", 
        "arm_group": {
            "arm_group_label": "Saxagliptin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is an open-label, cohort study to evaluate the potential mechanisms of\n      Saxagliptin in the treatment of patients with type 2 diabetes (T2DM) using a comprehensive\n      metabolomic method, in combination with fingerprint analysis and target analysis. It is a\n      sub-study of STUDY: D168L00008."
        }, 
        "brief_title": "Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients", 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All the subject Inclusion Criteria should be referred to STUDY: D168L00008.\n\n        Briefly\n\n          1. Provision of informed consent prior to any study specific procedures\n\n          2. Diagnosed with type 2 diabetes\n\n          3. Men or women who are 18 years of age.\n\n          4. Patients should be drug na\u00efve or treated with metformin alone on stable doses of for\n             at least continues 8 weeks.\n\n          5. HbA1c are between 7.5% and 11.0%\n\n        Exclusion Criteria:\n\n          -  All the subject Exclusion Criteria should be referred to STUDY: D168L00008.\n\n        Briefly\n\n          1. Pregnant or breastfeeding patients.\n\n          2. Insulin therapy within one year of enrolment(with the exception of insulin therapy\n             during a hospitalization or use in gestational diabetes).\n\n          3. Previous treatment with any dipeptidyl peptidase-IV (DPP-IV) inhibitors or\n             Glucagon-like peptide-1 (GLP-1) analogue.\n\n          4. History of administration of any antihyperglycemic therapy (other than metformin)\n             during the 8 weeks prior to Visit 1(12 weeks for previous TZD).\n\n          5. Treatment with systemic glucocorticoids other than replacement therapy. Inhaled,local\n             injected and topical use of glucocorticoids is allowed.\n\n          6. Treatment with strong cytochrome P450 inhibitors.\n\n          7. Gastrointestinal surgery that could impact the absorption of study drug.\n\n          8. Contraindications to therapy as outlined in the saxagliptin package insert.\n\n          9. Hypersensitivity to saxagliptin\n\n         10. Have a history of, or currently have, acute or chronic pancreatitis.\n\n         11. Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar non-ketonic coma.\n\n         12. Any condition where, in the opinion of the investigator, participation in this study\n             may pose a significant risk to the patient or could render the patient unable to\n             successfully complete the study.\n\n         13. Fasting plasma glucose >15mmol/l."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1708", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768208", 
            "org_study_id": "CCEMD016"
        }, 
        "intervention": {
            "arm_group_label": "Saxagliptin", 
            "intervention_name": "Saxagliptin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Saxagliptin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 14, 2013", 
        "location": {
            "contact": {
                "email": "guangning@medmail.com.cn", 
                "last_name": "Guang Ning, MD, PHD", 
                "phone": "64370045", 
                "phone_ext": "665340"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200025"
                }, 
                "name": "Shanghai Jiao Tong University School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "guangning@medmail.com.cn", 
            "last_name": "Guang Ning, MD, PHD", 
            "phone": "64370045", 
            "phone_ext": "665340"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of the study is to compare the different metabolomic profiling at baseline (before treatment) and at the end of the study drug administration(24 weeks) using a Liquid Chromatography-Mass Spectrometry (LC-MS) analysis.", 
            "measure": "The primary objective of the study is to evaluate the changes in the metabolomic parameters before and after Saxagliptin treatment in type 2 diabetic patients.", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768208"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Jiao Tong University School of Medicine", 
            "investigator_full_name": "Guang Ning", 
            "investigator_title": "the vice-president of Ruijin Hospital, Shanghai JiaoTong University School of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Jiao Tong University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}